#SARS-CoV-2

The update aims to help the public better protect themselves and understand their risk.

New studies offer evidence that an unexpected virus plays a role—but it needs a helper.

Antibody levels decrease substantially within three months after a booster, according to new clinical trial data.

The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.

Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.

After a long wait, the FDA authorizes Pfizer and Moderna vaccines for children as young as 6 months old.

The virus can be transmitted via respiratory droplets at close range, but it does not spread through the air over longer distances.

Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.

Approximately 1 in 3 Americans 65 and older who completed their initial vaccination round still have not received a first booster shot.

Nearly 200 cases of pediatric hepatitis have now been reported in more than a dozen countries and several states.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.

Immunocompromised people ages 12 and older are also eligible for an additional shot.

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.